Cargando…

GRK3 is a poor prognosticator and serves as a therapeutic target in advanced gastric adenocarcinoma

BACKGROUND: G protein-coupled receptor (GPCR) is the most targeted protein family by the FDA-approved drugs. GPCR-kinase 3 (GRK3) is critical for GPCR signaling. Our genomic analysis showed that GRK3 expression correlated with poor prognosis of gastric adenocarcinoma (GAC) patients. However, GRK3’s...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Yuan, Fan, Yibo, Xu, Jinbang, Huo, Longfei, Scott, Ailing W., Jin, Jiankang, Yang, Boxuan, Shao, Shan, Ma, Lang, Wang, Ying, Yao, Xiaodan, Pool Pizzi, Melissa, Sewastjanow Da Silva, Matheus, Zhang, Guoliang, Zhuo, Lijuan, Cho, Eun Jeong, Dalby, Kevin N., Shanbhag, Namita D., Wang, Zhenning, Li, Wenliang, Song, Shumei, Ajani, Jaffer A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9396876/
https://www.ncbi.nlm.nih.gov/pubmed/35996148
http://dx.doi.org/10.1186/s13046-022-02463-6
_version_ 1784772015707652096
author Li, Yuan
Fan, Yibo
Xu, Jinbang
Huo, Longfei
Scott, Ailing W.
Jin, Jiankang
Yang, Boxuan
Shao, Shan
Ma, Lang
Wang, Ying
Yao, Xiaodan
Pool Pizzi, Melissa
Sewastjanow Da Silva, Matheus
Zhang, Guoliang
Zhuo, Lijuan
Cho, Eun Jeong
Dalby, Kevin N.
Shanbhag, Namita D.
Wang, Zhenning
Li, Wenliang
Song, Shumei
Ajani, Jaffer A.
author_facet Li, Yuan
Fan, Yibo
Xu, Jinbang
Huo, Longfei
Scott, Ailing W.
Jin, Jiankang
Yang, Boxuan
Shao, Shan
Ma, Lang
Wang, Ying
Yao, Xiaodan
Pool Pizzi, Melissa
Sewastjanow Da Silva, Matheus
Zhang, Guoliang
Zhuo, Lijuan
Cho, Eun Jeong
Dalby, Kevin N.
Shanbhag, Namita D.
Wang, Zhenning
Li, Wenliang
Song, Shumei
Ajani, Jaffer A.
author_sort Li, Yuan
collection PubMed
description BACKGROUND: G protein-coupled receptor (GPCR) is the most targeted protein family by the FDA-approved drugs. GPCR-kinase 3 (GRK3) is critical for GPCR signaling. Our genomic analysis showed that GRK3 expression correlated with poor prognosis of gastric adenocarcinoma (GAC) patients. However, GRK3’s functions and clinical utility in GAC progression and metastases are unknown. METHODS: We studied GRK3 expression in normal, primary, and metastatic GAC tissues. We identified a novel GRK3 inhibitor, LD2, through a chemical-library screen. Through genetic and pharmacologic modulations of GRK3, a series of functional and molecular studies were performed in vitro and in vivo. Impact of GRK3 on YAP1 and its targets was determined. RESULTS: GRK3 was overexpressed in GAC tissues compared to normal and was even higher in peritoneal metastases. Overexpression (OE) of GRK3 was significantly associated with shorter survival. Upregulation of GRK3 in GAC cells increased cell invasion, colony formation, and proportion of ALDH1(+) cells, while its downregulation reduced these attributes. Further, LD2 potently and specifically inhibited GRK3, but not GRK2, a very similar kinase to GRK3. LD2 highly suppressed GAC cells’ malignant phenotypes in vitro. Mechanistically, GRK3 upregulated YAP1 in GAC tissues and its transcriptional downstream targets: SOX9, Birc5, Cyr61 and CTGF. Knockdown (KD) YAP1 rescued the phenotypes of GRK3 OE in GAC cells. GRK3 OE significantly increased tumor growth but LD2 inhibited tumor growth in the PDX model and dramatically suppressed peritoneal metastases induced by GRK3 OE. CONCLUSIONS: GRK3, a poor prognosticator for survival, conferred aggressive phenotype. Genetic silencing of GRK3 or its inhibitor LD2 blunted GRK3-conferred malignant attributes, suggesting GRK3 as a novel therapeutic target in advanced GAC. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13046-022-02463-6.
format Online
Article
Text
id pubmed-9396876
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-93968762022-08-24 GRK3 is a poor prognosticator and serves as a therapeutic target in advanced gastric adenocarcinoma Li, Yuan Fan, Yibo Xu, Jinbang Huo, Longfei Scott, Ailing W. Jin, Jiankang Yang, Boxuan Shao, Shan Ma, Lang Wang, Ying Yao, Xiaodan Pool Pizzi, Melissa Sewastjanow Da Silva, Matheus Zhang, Guoliang Zhuo, Lijuan Cho, Eun Jeong Dalby, Kevin N. Shanbhag, Namita D. Wang, Zhenning Li, Wenliang Song, Shumei Ajani, Jaffer A. J Exp Clin Cancer Res Research BACKGROUND: G protein-coupled receptor (GPCR) is the most targeted protein family by the FDA-approved drugs. GPCR-kinase 3 (GRK3) is critical for GPCR signaling. Our genomic analysis showed that GRK3 expression correlated with poor prognosis of gastric adenocarcinoma (GAC) patients. However, GRK3’s functions and clinical utility in GAC progression and metastases are unknown. METHODS: We studied GRK3 expression in normal, primary, and metastatic GAC tissues. We identified a novel GRK3 inhibitor, LD2, through a chemical-library screen. Through genetic and pharmacologic modulations of GRK3, a series of functional and molecular studies were performed in vitro and in vivo. Impact of GRK3 on YAP1 and its targets was determined. RESULTS: GRK3 was overexpressed in GAC tissues compared to normal and was even higher in peritoneal metastases. Overexpression (OE) of GRK3 was significantly associated with shorter survival. Upregulation of GRK3 in GAC cells increased cell invasion, colony formation, and proportion of ALDH1(+) cells, while its downregulation reduced these attributes. Further, LD2 potently and specifically inhibited GRK3, but not GRK2, a very similar kinase to GRK3. LD2 highly suppressed GAC cells’ malignant phenotypes in vitro. Mechanistically, GRK3 upregulated YAP1 in GAC tissues and its transcriptional downstream targets: SOX9, Birc5, Cyr61 and CTGF. Knockdown (KD) YAP1 rescued the phenotypes of GRK3 OE in GAC cells. GRK3 OE significantly increased tumor growth but LD2 inhibited tumor growth in the PDX model and dramatically suppressed peritoneal metastases induced by GRK3 OE. CONCLUSIONS: GRK3, a poor prognosticator for survival, conferred aggressive phenotype. Genetic silencing of GRK3 or its inhibitor LD2 blunted GRK3-conferred malignant attributes, suggesting GRK3 as a novel therapeutic target in advanced GAC. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13046-022-02463-6. BioMed Central 2022-08-23 /pmc/articles/PMC9396876/ /pubmed/35996148 http://dx.doi.org/10.1186/s13046-022-02463-6 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Li, Yuan
Fan, Yibo
Xu, Jinbang
Huo, Longfei
Scott, Ailing W.
Jin, Jiankang
Yang, Boxuan
Shao, Shan
Ma, Lang
Wang, Ying
Yao, Xiaodan
Pool Pizzi, Melissa
Sewastjanow Da Silva, Matheus
Zhang, Guoliang
Zhuo, Lijuan
Cho, Eun Jeong
Dalby, Kevin N.
Shanbhag, Namita D.
Wang, Zhenning
Li, Wenliang
Song, Shumei
Ajani, Jaffer A.
GRK3 is a poor prognosticator and serves as a therapeutic target in advanced gastric adenocarcinoma
title GRK3 is a poor prognosticator and serves as a therapeutic target in advanced gastric adenocarcinoma
title_full GRK3 is a poor prognosticator and serves as a therapeutic target in advanced gastric adenocarcinoma
title_fullStr GRK3 is a poor prognosticator and serves as a therapeutic target in advanced gastric adenocarcinoma
title_full_unstemmed GRK3 is a poor prognosticator and serves as a therapeutic target in advanced gastric adenocarcinoma
title_short GRK3 is a poor prognosticator and serves as a therapeutic target in advanced gastric adenocarcinoma
title_sort grk3 is a poor prognosticator and serves as a therapeutic target in advanced gastric adenocarcinoma
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9396876/
https://www.ncbi.nlm.nih.gov/pubmed/35996148
http://dx.doi.org/10.1186/s13046-022-02463-6
work_keys_str_mv AT liyuan grk3isapoorprognosticatorandservesasatherapeutictargetinadvancedgastricadenocarcinoma
AT fanyibo grk3isapoorprognosticatorandservesasatherapeutictargetinadvancedgastricadenocarcinoma
AT xujinbang grk3isapoorprognosticatorandservesasatherapeutictargetinadvancedgastricadenocarcinoma
AT huolongfei grk3isapoorprognosticatorandservesasatherapeutictargetinadvancedgastricadenocarcinoma
AT scottailingw grk3isapoorprognosticatorandservesasatherapeutictargetinadvancedgastricadenocarcinoma
AT jinjiankang grk3isapoorprognosticatorandservesasatherapeutictargetinadvancedgastricadenocarcinoma
AT yangboxuan grk3isapoorprognosticatorandservesasatherapeutictargetinadvancedgastricadenocarcinoma
AT shaoshan grk3isapoorprognosticatorandservesasatherapeutictargetinadvancedgastricadenocarcinoma
AT malang grk3isapoorprognosticatorandservesasatherapeutictargetinadvancedgastricadenocarcinoma
AT wangying grk3isapoorprognosticatorandservesasatherapeutictargetinadvancedgastricadenocarcinoma
AT yaoxiaodan grk3isapoorprognosticatorandservesasatherapeutictargetinadvancedgastricadenocarcinoma
AT poolpizzimelissa grk3isapoorprognosticatorandservesasatherapeutictargetinadvancedgastricadenocarcinoma
AT sewastjanowdasilvamatheus grk3isapoorprognosticatorandservesasatherapeutictargetinadvancedgastricadenocarcinoma
AT zhangguoliang grk3isapoorprognosticatorandservesasatherapeutictargetinadvancedgastricadenocarcinoma
AT zhuolijuan grk3isapoorprognosticatorandservesasatherapeutictargetinadvancedgastricadenocarcinoma
AT choeunjeong grk3isapoorprognosticatorandservesasatherapeutictargetinadvancedgastricadenocarcinoma
AT dalbykevinn grk3isapoorprognosticatorandservesasatherapeutictargetinadvancedgastricadenocarcinoma
AT shanbhagnamitad grk3isapoorprognosticatorandservesasatherapeutictargetinadvancedgastricadenocarcinoma
AT wangzhenning grk3isapoorprognosticatorandservesasatherapeutictargetinadvancedgastricadenocarcinoma
AT liwenliang grk3isapoorprognosticatorandservesasatherapeutictargetinadvancedgastricadenocarcinoma
AT songshumei grk3isapoorprognosticatorandservesasatherapeutictargetinadvancedgastricadenocarcinoma
AT ajanijaffera grk3isapoorprognosticatorandservesasatherapeutictargetinadvancedgastricadenocarcinoma